Hosted on MSN

Ocular gains as Wet AMD trial for lead asset reaches enrollment target

Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R for its lead asset Axpaxli for the eye disorder wet age-related macular ...
MedPage Today

Wet AMD: Novel Insights into Its Risk Factors

—A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...
Healio

Faricimab extends treatment intervals in treatment-naive wet AMD

Patients with treatment-naive neovascular age-related macular degeneration have positive outcomes with faricimab at 1 year, ...
Healio

‘One-and-done’ gene therapy could shift wet AMD treatment paradigm

Please provide your email address to receive an email when new articles are posted on . Sura-vec injection reduced the annualized anti-VEGF injection rate by 76% with a high dose and 77% with a low ...
News Medical

U.K Ophthalmologists lead in treatment of wet AMD patients with Oraya therapy across europe

Oraya Therapeutics Inc. announced today at the Royal College of Ophthalmologists Annual Congress that U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet ...
Seeking Alpha

Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade)

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI mechanism. DEXTENZA sales are declining, making Ocular increasingly dependent on ...